Engineered Probiotic Bacteria Deliver an Anti-Arthritis Peptide Through the Gut

Researchers engineered a probiotic bacterium (Lactobacillus reuteri) to produce and secrete ShK-235, a peptide that blocks the Kv1.3 potassium channel on inflammatory T cells. When fed to rats, a single oral dose delivered enough functional peptide into the bloodstream to reduce skin inflammation, and daily oral dosing dramatically reduced disease severity in a rat model of rheumatoid arthritis. The peptide did not trigger an immune response against itself, suggesting the probiotic delivery approach avoids the immunogenicity problems that plague many injected peptide drugs.

The team genetically engineered L. reuteri to secrete the Kv1.3-blocking peptide ShK-235 on demand. They verified the secreted peptide blocked Kv1.3 channels and selectively inhibited inflammatory T cell proliferation in cell cultures. In rats, they tested single and daily oral doses against two disease models: delayed-type hypersensitivity (atopic dermatitis model) and a rheumatoid arthritis model, measuring clinical disease scores, joint inflammation, and anti-peptide antibody responses.

This study solves two major problems at once: oral delivery of a peptide (normally impossible because the gut destroys peptides) and targeted immunosuppression without broad immune shutdown. Using a probiotic as a living factory that continuously produces a therapeutic peptide in the gut is a creative approach that could transform how autoimmune diseases are treated — replacing daily injections with a simple oral dose.

This study sits at the intersection of three hot fields: engineered probiotics, peptide therapeutics, and autoimmune disease. The concept of using living bacteria as drug factories in the gut is gaining traction, with multiple companies developing similar approaches for other diseases. If this platform works in humans, it could make peptide therapies accessible as simple oral products — no injections, no refrigeration, no absorption enhancers needed.

This is an animal study in rats — translation to humans faces significant hurdles including regulatory approval of genetically modified probiotics, differences in human vs rat gut environments, and the need to verify adequate peptide absorption in humans. Long-term safety of colonization with engineered bacteria is unknown. The specific rat disease models don't perfectly replicate human rheumatoid arthritis.